IL131096A - Method for preparing a composition derived from muscle tissue - Google Patents
Method for preparing a composition derived from muscle tissueInfo
- Publication number
- IL131096A IL131096A IL13109699A IL13109699A IL131096A IL 131096 A IL131096 A IL 131096A IL 13109699 A IL13109699 A IL 13109699A IL 13109699 A IL13109699 A IL 13109699A IL 131096 A IL131096 A IL 131096A
- Authority
- IL
- Israel
- Prior art keywords
- composition
- matter
- biologically active
- cells
- tissue
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 128
- 210000003205 muscle Anatomy 0.000 title claims abstract description 27
- 238000000034 method Methods 0.000 title claims abstract description 17
- 239000006228 supernatant Substances 0.000 claims abstract description 12
- 241001465754 Metazoa Species 0.000 claims abstract description 10
- 239000007788 liquid Substances 0.000 claims abstract description 10
- 210000001519 tissue Anatomy 0.000 claims abstract description 9
- 230000002001 anti-metastasis Effects 0.000 claims abstract description 7
- 230000001767 chemoprotection Effects 0.000 claims abstract description 7
- 239000000126 substance Substances 0.000 claims abstract description 5
- 238000012258 culturing Methods 0.000 claims abstract description 3
- 210000004027 cell Anatomy 0.000 claims description 42
- 238000011282 treatment Methods 0.000 claims description 31
- 230000035755 proliferation Effects 0.000 claims description 23
- 210000000265 leukocyte Anatomy 0.000 claims description 17
- 210000000440 neutrophil Anatomy 0.000 claims description 14
- 230000000973 chemotherapeutic effect Effects 0.000 claims description 12
- 230000004071 biological effect Effects 0.000 claims description 11
- 238000002360 preparation method Methods 0.000 claims description 10
- 210000004881 tumor cell Anatomy 0.000 claims description 10
- 230000002401 inhibitory effect Effects 0.000 claims description 8
- 241000287828 Gallus gallus Species 0.000 claims description 6
- 238000002512 chemotherapy Methods 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 238000000746 purification Methods 0.000 claims description 5
- 238000000605 extraction Methods 0.000 claims description 3
- 231100000331 toxic Toxicity 0.000 claims description 3
- 230000002588 toxic effect Effects 0.000 claims description 3
- 230000004936 stimulating effect Effects 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 description 27
- 201000011510 cancer Diseases 0.000 description 23
- 241000699670 Mus sp. Species 0.000 description 21
- 230000000694 effects Effects 0.000 description 17
- 239000002246 antineoplastic agent Substances 0.000 description 13
- 229940044683 chemotherapy drug Drugs 0.000 description 13
- 210000002798 bone marrow cell Anatomy 0.000 description 10
- 206010061289 metastatic neoplasm Diseases 0.000 description 9
- 230000002265 prevention Effects 0.000 description 8
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 7
- 206010025323 Lymphomas Diseases 0.000 description 7
- 229960004397 cyclophosphamide Drugs 0.000 description 7
- 238000004128 high performance liquid chromatography Methods 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 235000013330 chicken meat Nutrition 0.000 description 6
- 231100000433 cytotoxic Toxicity 0.000 description 5
- 230000001472 cytotoxic effect Effects 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 210000004072 lung Anatomy 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 238000005194 fractionation Methods 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 238000010348 incorporation Methods 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 230000003211 malignant effect Effects 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 201000001441 melanoma Diseases 0.000 description 4
- 230000001394 metastastic effect Effects 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 238000004007 reversed phase HPLC Methods 0.000 description 4
- 229940104230 thymidine Drugs 0.000 description 4
- 241001529936 Murinae Species 0.000 description 3
- 239000012979 RPMI medium Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 231100001274 therapeutic index Toxicity 0.000 description 3
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 2
- 206010027480 Metastatic malignant melanoma Diseases 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000000287 crude extract Substances 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 239000002254 cytotoxic agent Substances 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000000890 drug combination Substances 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 235000013372 meat Nutrition 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 208000021039 metastatic melanoma Diseases 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- 210000000689 upper leg Anatomy 0.000 description 2
- 102000018997 Growth Hormone Human genes 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 206010027458 Metastases to lung Diseases 0.000 description 1
- 206010034203 Pectus Carinatum Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000011210 chromatographic step Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000010411 cooking Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000000431 effect on proliferation Effects 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 230000002410 myeloprotective effect Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 235000015277 pork Nutrition 0.000 description 1
- 239000013630 prepared media Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 235000014122 turkey meat Nutrition 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/34—Muscles; Smooth muscle cells; Heart; Cardiac stem cells; Myoblasts; Myocytes; Cardiomyocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Vascular Medicine (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IL13109699A IL131096A (en) | 1999-07-26 | 1999-07-26 | Method for preparing a composition derived from muscle tissue |
| AT00944187T ATE338559T1 (de) | 1999-07-26 | 2000-07-06 | Aus muskeln abstammenden wirkstoffe enthaltende zusammensetzung |
| EP00944187A EP1204418B1 (de) | 1999-07-26 | 2000-07-06 | Aus muskeln abstammenden wirkstoffe enthaltende zusammensetzung |
| US09/700,745 US6537587B1 (en) | 1999-07-26 | 2000-07-06 | Compositions containing muscle-derived active agents |
| PCT/IL2000/000395 WO2001007060A1 (en) | 1999-07-26 | 2000-07-06 | Compositions containing muscle-derived active agents |
| CA002378726A CA2378726A1 (en) | 1999-07-26 | 2000-07-06 | Compositions containing muscle-derived active agents |
| DE60030567T DE60030567T2 (de) | 1999-07-26 | 2000-07-06 | Aus muskeln abstammenden wirkstoffe enthaltende zusammensetzung |
| JP2001511943A JP2003505425A (ja) | 1999-07-26 | 2000-07-06 | 筋由来の活性作用物質を含有する組成物 |
| AU58418/00A AU758856C (en) | 1999-07-26 | 2000-07-06 | Compositions containing muscle-derived active agents |
| MXPA02000915A MXPA02000915A (es) | 1999-07-26 | 2000-07-06 | Composiciones que contienen agentes activos derivados de musculo. |
| CNB008122962A CN1195529C (zh) | 1999-07-26 | 2000-07-06 | 含有来源于肌肉的活性成分的组合物 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IL13109699A IL131096A (en) | 1999-07-26 | 1999-07-26 | Method for preparing a composition derived from muscle tissue |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL131096A0 IL131096A0 (en) | 2001-01-28 |
| IL131096A true IL131096A (en) | 2004-09-27 |
Family
ID=11073063
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL13109699A IL131096A (en) | 1999-07-26 | 1999-07-26 | Method for preparing a composition derived from muscle tissue |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US6537587B1 (de) |
| EP (1) | EP1204418B1 (de) |
| JP (1) | JP2003505425A (de) |
| CN (1) | CN1195529C (de) |
| AT (1) | ATE338559T1 (de) |
| AU (1) | AU758856C (de) |
| CA (1) | CA2378726A1 (de) |
| DE (1) | DE60030567T2 (de) |
| IL (1) | IL131096A (de) |
| MX (1) | MXPA02000915A (de) |
| WO (1) | WO2001007060A1 (de) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6790839B2 (en) | 1999-01-07 | 2004-09-14 | Can-Fite Biopharma Ltd. | Pharmaceutical administration of adenosine agonists |
| IL127947A0 (en) | 1999-01-07 | 1999-11-30 | Can Fite Technologies Ltd | Pharmaceutical use of adenosine agonists |
| IL131096A (en) | 1999-07-26 | 2004-09-27 | Can Fite Technologies Ltd | Method for preparing a composition derived from muscle tissue |
| IL133680A0 (en) | 1999-09-10 | 2001-04-30 | Can Fite Technologies Ltd | Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist |
| JP4712256B2 (ja) * | 2001-09-28 | 2011-06-29 | 東海物産株式会社 | 高品位チキンエキス含有機能性食品とその製造方法 |
| JP4712257B2 (ja) * | 2001-09-28 | 2011-06-29 | 東海物産株式会社 | チキンエキス膜処理物及びその含有物の製造法 |
| EP1765981A4 (de) * | 2004-06-11 | 2007-09-12 | Victorian Tissue Engineering C | Gewebematerial und aus muskel gewonnene matrix |
| CN100335066C (zh) * | 2005-04-07 | 2007-09-05 | 暨南大学 | 一种肌肉匀浆提取物及其制备方法与应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR1345565A (fr) * | 1962-01-19 | 1963-12-13 | Rolland Lab A | Procédé pour l'obtention d'extraits totaux plus généralement orginaires de tissus viants |
| ZA847349B (en) * | 1983-10-05 | 1985-04-24 | Solco Basel Ag | Process for the preparation of a biologically active extract |
| US5242692A (en) * | 1990-07-10 | 1993-09-07 | Bar Ilan University | Anti-metastatic factor |
| IL111021A0 (en) * | 1994-09-22 | 1994-11-28 | Mor Research Applic Ltd | Factor derived from muscle cells |
| IL121272A (en) | 1997-07-10 | 2000-06-01 | Can Fite Technologies Ltd | Pharmaceutical compositions comprising adenosine and their use for treating or preventing leukopenia |
| IL131096A (en) | 1999-07-26 | 2004-09-27 | Can Fite Technologies Ltd | Method for preparing a composition derived from muscle tissue |
-
1999
- 1999-07-26 IL IL13109699A patent/IL131096A/en not_active IP Right Cessation
-
2000
- 2000-07-06 EP EP00944187A patent/EP1204418B1/de not_active Expired - Lifetime
- 2000-07-06 CA CA002378726A patent/CA2378726A1/en not_active Abandoned
- 2000-07-06 US US09/700,745 patent/US6537587B1/en not_active Expired - Fee Related
- 2000-07-06 JP JP2001511943A patent/JP2003505425A/ja active Pending
- 2000-07-06 AT AT00944187T patent/ATE338559T1/de not_active IP Right Cessation
- 2000-07-06 WO PCT/IL2000/000395 patent/WO2001007060A1/en not_active Ceased
- 2000-07-06 MX MXPA02000915A patent/MXPA02000915A/es active IP Right Grant
- 2000-07-06 CN CNB008122962A patent/CN1195529C/zh not_active Expired - Fee Related
- 2000-07-06 DE DE60030567T patent/DE60030567T2/de not_active Expired - Fee Related
- 2000-07-06 AU AU58418/00A patent/AU758856C/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO2001007060A1 (en) | 2001-02-01 |
| DE60030567D1 (de) | 2006-10-19 |
| AU758856C (en) | 2003-11-20 |
| ATE338559T1 (de) | 2006-09-15 |
| CN1195529C (zh) | 2005-04-06 |
| CA2378726A1 (en) | 2001-02-01 |
| DE60030567T2 (de) | 2007-05-31 |
| AU5841800A (en) | 2001-02-13 |
| MXPA02000915A (es) | 2003-07-14 |
| CN1399553A (zh) | 2003-02-26 |
| US6537587B1 (en) | 2003-03-25 |
| EP1204418A1 (de) | 2002-05-15 |
| JP2003505425A (ja) | 2003-02-12 |
| EP1204418B1 (de) | 2006-09-06 |
| IL131096A0 (en) | 2001-01-28 |
| AU758856B2 (en) | 2003-04-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Jurin et al. | Antitumorous and immunomodulatory effects of the Viscum album L. preparation Isorel | |
| US6537587B1 (en) | Compositions containing muscle-derived active agents | |
| US20030143282A1 (en) | Adenosine A3 receptor agonist | |
| JP2002302447A (ja) | 局所投与用癌治療剤 | |
| EP1150697B1 (de) | Hochmolekulargewicht extrakte aus convolvulus arvensis (acker-winde) | |
| Amagase et al. | Epidermal growth factor receptor‐mediated selective cytotoxicity of antitumor agents toward human xenografts and murine syngeneic solid tumors | |
| KR20160141748A (ko) | 항암제 및 부작용 경감제 | |
| EP0782452B1 (de) | Wachstumsregulator | |
| CN114949000A (zh) | 麝香提取物及其增强car-t细胞疗效的应用 | |
| EP4248964A1 (de) | Pharmazeutische zusammensetzung zur behandlung von sepsis und verwendung davon | |
| KR20010101065A (ko) | 표고버섯 균사체 추출물 유래의 ｌａｋ 활성증강물질 및이를 함유하는 ｌａｋ 활성증강용 제제 | |
| US20040137095A1 (en) | Phytochemotherapy for cancer | |
| FI77157B (fi) | Foerfarande foer framstaellning av glykobunden antigen och foerfarande foer framstaellning av foer kancerceller toxiska lymfocyter, som aer specifika mot denna antigen. | |
| MXPA97002174A (en) | Celu growth regulator | |
| Ivankovic et al. | The influence of medicinal mushroom preparations on mouse tumors | |
| US20070224214A1 (en) | Composition Exerting Physiological Activity Via Biological Immune Mechanism | |
| KR20230148540A (ko) | 항염, 항섬유화를 포함한 신장손상 개선 효과를 갖는 쇠비름 추출물 | |
| KR100492940B1 (ko) | 항종양활성 증진용 조성물 | |
| US6599538B2 (en) | High molecular weight extracts of Convolvulus arvensis (field bindweed) and Polygonum convolvulus (wild buckwheat) | |
| CN121102317A (zh) | 一种治疗非小细胞肺癌中药水提取物及其制备方法与应用 | |
| KR20020009929A (ko) | 간암 치료 및 예방용 의약 조성물 | |
| HK40079888A (en) | Musk extract and application thereof in enhancing effect of car-t cells | |
| JPH11116491A (ja) | 血清由来の新規な抗腫瘍性物質ｓ３、その製造法及びそれを含む抗腫瘍剤 | |
| CN111035758A (zh) | 药物组合物及其应用、无菌容器和试剂盒 | |
| HUT74576A (en) | Method for preparing medical preparatives of bone marrow protecting and antineoplastic effects |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed | ||
| KB | Patent renewed | ||
| MM9K | Patent not in force due to non-payment of renewal fees |